Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Google Secures Pentagon AI Deal for Classified Projects 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Mechelen, Belgium; 21 April 2017, 22.01 CET; regulated information - Galapagos NV (Euronext: GLPG; Nasdaq: GLPG) announces a share capital increase as a result of a public offering of American Depositary Shares.
In accordance with Belgian transparency legislation[1], Galapagos notes that its total share capital currently amounts to €274,854,440.18; the total number of securities conferring voting rights is 50,815,648, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,369,337, which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 510 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.
CONTACT
| Investors: | Media: |
| Elizabeth Goodwin | Evelyn Fox |
| VP IR & Corporate Communications +1 781 460 1784 | Director Communications +31 6 53 591 999 [email protected] |
| Paul van der Horst Director IR & Business Development +31 6 53 725 199 | |
| [email protected] |
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/1aceb031-e307-4569-ad15-3d080a3156ca
